Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval [Seeking Alpha]
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Phase 3 NORSE EIGHT study underway using ONS-5010 for the treatment of patients with Wet-AMD; Data expected to be released in Q4 of 2024. Pending the primary endpoint of BCVA in NORSE EIGHT being met with statistical significance, BLA filing of ONS-5010 for Wet-AMD expected in 2024. The anti-VEGF market size is projected to reach $13.54 billion by 2030. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Outlook Therapeutics NASDAQ: OTLK ) has made significant progress in advancing the use of its drug ONS-5010, which is being developed for the treatment of patients with wet age-related macular degeneration [Wet-AMD]. The use of this anti-VEGF drug is being explored in several studies, but the company is on the right track with de-risked events as it relates to the regulatory side of things, despite the fact that it had a major roadblock on the past with the FDA. Not only was it able to get to the FDA to agree to a Spe
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase [Yahoo! Finance]Yahoo! Finance
- Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseGlobeNewswire
- Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionGlobeNewswire
- Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.MarketBeat
- Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target raised by analysts at HC Wainwright from $1.50 to $30.00. They now have a "buy" rating on the stock.MarketBeat
OTLK
Earnings
- 2/14/24 - Beat
OTLK
Sec Filings
- 4/26/24 - Form S-3
- 4/17/24 - Form SC
- 4/17/24 - Form 4
- OTLK's page on the SEC website